Circulating Tumor Cells and Dnas in Prostate Tumors Publisher



Aghamir SMK¹ ; Rahimnia A¹ ; Zadeh SST¹ ; Roudgari H^{2, 3} Show Affiliations
Source: Liquid Biopsy in Urogenital Cancers and its Clinical Utility Published:2022

Abstract

Prostate cancer consists a great proportion of men’s cancers, and the 2020 report of Global Cancer Observatory claimed an incidence of nearly 1.5 million that caused 370, 000 deaths around the world. Its lifetime risk is 3.9%, which is a major concern of male adults. However, substantial improvements have taken place in the field of prostate cancer diagnosis and treatments, and it is still a major public health issue, even in developed countries. Tissue biopsy, as the routine method of prostate cancer diagnosis, is associated with a variety of complications and may not be sensitive enough for detecting the malignant tumor; thus, researches are still going on to find more reliable alternative method with less complication. Recently, liquid biopsy, which is a noninvasive analysis of several markers from body fluids including cell-free DNA, circulating tumor cells, RNAs, and exosomes, came into the center of scientists’ interest, with a number of advantageous over the traditional methods. The applicability of each subtypes of liquid biopsy in different malignancies is under investigation, especially in prostate cancer, and it is suggested that the benefits of liquid biopsy are not restricted to the diagnosis of prostate, but it may play a role in the prognostic assessments and treatment strategies too. Despite promising results inform many experimental and clinical studies, there are still several obstacles that limit the usage of liquid biopsy as a routine clinical practice. However, there are hopes that soon liquid biopsy will become an inseparable part of cancer diagnosis and management. © 2022 Elsevier Inc. All rights reserved.